“What gives us confidence in continued acceleration to the back half of the year is the incredible impact of truly differentiated innovation across our ortho portfolio.”

In context

“o the significant impact of one-timers in the quarter, which, to your point, have disproportionately impacted the Ortho business to the tune of roughly 480 basis points. There are three key drivers to that. Number one, the lapping of prior year change in walking implants revenue recognition, fewer selling days, and finally revenue disruption from the recent ortho transformation, which we announced in 2023. So when you actually look at our operational growth, when accounting for those, it would be closer to 2%. Now at the same time, I will say, Joanne, we are not satisfied. Our underlying performance was impacted by competitive pressures, primarily in spine and sports, which is partially offset by strong NPIs and commercial execution in categories like trauma, shoulder, and foot and ankle. What gives us confidence in continued acceleration to the back half of the year is the incredible impact of truly differentiated innovation across our ortho portfolio. In fact, in 2024, we had eighteen 510(k) approvals here in the US, and forty-five outside of the US across our portfolio. And what gives us confidence is this combination of having best-in-class implants with truly differentiated enabled technology such as Velas. In our Hips portfolio, we believe we're going to see continued performance on the back of our focus on two-point-o. In these, we have seen a slowdown in revisions where I think you know we are historically number one, but feel very confident about continued momentum in primary with the combination of Attun and Velas which is now available in thirty markets. We have a hundred and ten thousand procedures, and as you probably know, we're now launching the Velocirune knee in the coming quarters. In trauma, this was a standout quarter”